On January 10th, Jiangsu Hengrui Pharmaceuticals (600276) announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., received a notice of approval from the National Medical Products Administration for the clinical trial of SHR-1819 injection. Clinical trials will be conducted in the near future for the indication of chronic spontaneous urticaria. The subsidiary, Suzhou Shengdiya Biomedical Co., Ltd., also received a notice of approval for the clinical trial of SHR-4375 injection, which is proposed for the treatment of advanced malignant solid tumors.
恒瑞医药：获得两份药物临床试验批准通知书
Jiangsu Hengrui Pharmaceuticals: Received two notices of approval for drug clinical trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha